| 000 | 01510 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517132320.0 | ||
| 264 | 0 | _c20170425 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1002/cpt.558 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aArwood, M J | |
| 245 | 0 | 0 |
_aAnticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cMay 2017 |
||
| 300 |
_a675-683 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 | _aAlleles |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C9 _xgenetics |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEndpoint Determination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 |
_aVitamin K Epoxide Reductases _xgenetics |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aDeng, J | |
| 700 | 1 | _aDrozda, K | |
| 700 | 1 | _aPugach, O | |
| 700 | 1 | _aNutescu, E A | |
| 700 | 1 | _aSchmidt, S | |
| 700 | 1 | _aDuarte, J D | |
| 700 | 1 | _aCavallari, L H | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 101 _gno. 5 _gp. 675-683 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt.558 _zAvailable from publisher's website |
| 999 |
_c26739813 _d26739813 |
||